422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma

• Paul Young,
• Erol Wiegert,
• Tanner Miest,
• Bradley Leibovich,
• Stephen Bardot,
• Stephen Boorjian,
• Mark Gonzalgo,
• Loren Herrera-Hernandez,
• Matthew Tollefson,
• Jeffrey Karnes,
• Paige Nichols,
• Tessa Kroeninger,
• Rachel Graham,
• Carole Lahana,
• Monica Reckner,
• Alysha Newsom,
• Nandakumar Packiriswamy,
• Janice Anoka,
• Kah Whye Peng,
• Alice Bexon,
• Shruthi Naik

Affiliations

Paul Young

The Intensive Care Research Programme, Medical Research Institute of New Zealand, Wellington, New Zealand

Erol Wiegert

8Bexon Clinical Consulting, Upper Montclair, USA

Tanner Miest

1University of Texas and Mayo Clinic, Houston, TX, USA

Bradley Leibovich

2Mayo Clinic, Rochester, MN, USA

Stephen Bardot

3Ochsner Clinic, New Orleans, LA, USA

Stephen Boorjian

2Mayo Clinic, Rochester, MN, USA

Mark Gonzalgo

4University of Miami, Miami, FL, USA

Loren Herrera-Hernandez

2Mayo Clinic, Rochester, MN, USA

Matthew Tollefson

2Mayo Clinic, Rochester, MN, USA

Jeffrey Karnes

2Mayo Clinic, Rochester, MN, USA

Paige Nichols

2Mayo Clinic, Rochester, MN, USA

Tessa Kroeninger

2Mayo Clinic, Rochester, MN, USA

Rachel Graham

3Ochsner Clinic, New Orleans, LA, USA

Carole Lahana

4University of Miami, Miami, FL, USA

Monica Reckner

5Vyriad, Inc., Rochester, MN, USA

Alysha Newsom

2Mayo Clinic, Rochester, MN, USA

Nandakumar Packiriswamy

6Mayo Clinic and Vyriad Inc., Rochester, MN, USA

Janice Anoka

7Vyriad Inc., Rochester, MN, USA

Kah Whye Peng

2Mayo Clinic, Rochester, MN, USA

Alice Bexon

7Vyriad Inc., Rochester, MN, USA

Shruthi Naik

6Mayo Clinic and Vyriad Inc., Rochester, MN, USA